Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 6, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Prognostic tools in follicular lymphomas.

Stefano Luminari1, Maria Christina Cox, Antonella Montanini

  • 1Centro Oncologico Modenese, Dipartimento integrato di Oncologia, Ematologia e Malattie dell'Apparato Respiratorio, Università di Modena e Reggio Emilia, Modena, Italy. sluminari@unimore.it

Expert Review of Hematology
|November 19, 2010
PubMed
Summary

Prognostic indexes are crucial for follicular lymphoma (FL) patient care. New models like FLIPI2, incorporating clinical data and rituximab treatment, improve risk stratification for disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026
Same author

Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decade.

Annals of hematology·2026
Same author

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Leukemia & lymphoma·2026
Same author

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

JAMA oncology·2026
Same author

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis.

Cancers·2026
Same author

Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.

Blood cancer journal·2026

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Follicular lymphoma (FL) patient outcomes remain heterogeneous despite treatment advances.
  • Accurate prognostic indexes are essential for guiding treatment decisions and clinical trial design.

Purpose of the Study:

  • To review the evolution and importance of prognostic factors and scoring systems in follicular lymphoma.
  • To highlight the role of clinical data and newer models like FLIPI2 in risk stratification.

Main Methods:

  • Review of existing literature on prognostic factors in follicular lymphoma.
  • Analysis of the development and application of prognostic indexes, including FLIPI and FLIPI2.
  • Emphasis on the integration of clinical and biological data.

Related Experiment Videos

Last Updated: Jun 6, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Main Results:

  • The FL International Prognostic Index (FLIPI) is a key tool for assessing mortality risk.
  • FLIPI2, developed using prospective data including rituximab, stratifies patients into three risk categories for progression.
  • Clinical data remains the primary source for prognostic information due to challenges in validating biological factors.

Conclusions:

  • Prognostic indexes are vital for managing follicular lymphoma due to disease heterogeneity.
  • FLIPI2 offers improved risk stratification for patients treated with rituximab.
  • The study of prognosis in FL is dynamic, driven by evolving therapies and the need for validated prognostic tools.